🔗 Share this article

While the United States proceeds with historic changes to its vaccination recommendations, a particular individual has surfaced somewhat surprisingly: Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the pandemic and has focused upon potential deaths after COVID-19 vaccination in her brief position at the Food and Drug Administration.

Planned Changes to Childhood Immunization Program

Agency leaders had intended to reveal major revisions to the pediatric immunization program recently, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US out of step with many the global community with little proof for improved outcomes. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Høeg is set to present at the meeting. She was just designated interim head of the FDA’s CDER, the fifth individual to head the office this calendar year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain pediatric shot schedules in the US to become more like Denmark, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has little discernible background in medication creation, oversight or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the CDER, stated Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Previous directors of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that prior appointees who led the center have had.”

The drug center has an immense workload at the agency, Woodcock pointed out.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and all of those need to be looked after,” Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the job, which oversees over 5,000 staff members. “It’s a massive management job, if you execute it properly,” the former official said.

Official Statement and Controversial Initiatives

When asked about concerns about Høeg’s qualifications and whether this assignment signifies more teamwork among agency officials on immunizations, a press secretary responded that the “inquiries stem from incorrect assumptions”.

“Her experience is consistent with the responsibilities of her job,” the official stated, citing the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a controversial one-day drug-approval program that allegedly concerned her former heads. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Howard questioned. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the FDA seems to be moving towards less stringent regulations of all drugs, aside from immunizations.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if problematic, past, some experts have noted. She published a study using non-validated crowd-sourced reports to determine the rate of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming federal leadership encompassed altering guidelines for recently developed shots and ending “non-essential” immunizations, she said post-election on a online show. At the agency, Høeg has according to sources suggested excluding young men from getting Covid vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the data in a extremely deceptive, untruthful manner,” Howard said.

Taking Control and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|